Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-PPD Safety and Allergenicity in Healthy Volunteers and Tuberculosis Patients
CTR20232485Phase 2Completed
- Sponsor
- Chengdu Keen Biotechnology
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tuberculin purified protein derivative in Tuberculosis (TB), sponsored by Chengdu Keen Biotechnology. Started Aug 2023; status: completed.
02
Drugs
tuberculin purified protein derivative
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on CTR20232485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232485.